Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3166977 | 0.92 | KDM4E (0.39) | HPGDKDM4EMEN1NPC1ALDH1A1 | |
| SCHEMBL3171908 | 0.89 | SMN1; SMN2 (0.35) | HPGDKDM4EMEN1NPC1ALDH1A1 | |
| SCHEMBL3157828 | 0.81 | KDM4E (0.39) | HPGDKDM4EMEN1NPC1ALDH1A1 | |
| SCHEMBL3153612 | 0.81 | HTT (0.40) | HPGDKDM4EMEN1NPC1ALDH1A1 | |
| SCHEMBL3158527 | 0.81 | HTT (0.39) | HPGDKDM4EMEN1NPC1ALDH1A1 | |
| SCHEMBL3158482 | 0.80 | HTT (0.38) | HPGDKDM4EMEN1NPC1ALDH1A1 | |
| SCHEMBL7868663 | 0.80 | PGR (0.33) | — | |
| SCHEMBL7862024 | 0.79 | KDM4E (0.34) | HPGDKDM4EMEN1NPC1ALDH1A1 | |
| SCHEMBL7862035 | 0.77 | PGR (0.32) | — | |
| SCHEMBL9056690 | 0.77 | KDM4E (0.44) | HPGDKDM4EMEN1NPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1423387-B1 | PHOTOCHROMIC BIS-NAPHTHOPYRAN COMPOUNDS AND METHODS FOR THEIR MANUFACTURE | ESSILOR INT (FR) | 2010-03-17 | — | — | EP | disclosed |
| US-6939007-B2 | Photochromic bis-naphthopyran compounds and methods for their manufacture | ESSILOR INTERNATIONAL (COMPAGNIE GENERALE D'OPTIQUE) (FR) | 2005-09-06 | — | — | US | disclosed |
| US-6747145-B2 | COUPLING A PROPARGYL ALCOHOL WITH A NAPHTHOL IN THE PRESENCE OF A CATALYTIC AMOUNT OF AN ACID, A SOLVENT AND 3 ANGSTROM MOLECULAR SIEVE TO GENERATE NAPHTHOPYRAN COMPOUND | JOHNSON & JOHNSON VISION CARE, INC. | 2004-06-08 | — | — | US | disclosed |
| EP-1423387-A1 | PHOTOCHROMIC BIS-NAPHTHOPYRAN COMPOUNDS AND METHODS FOR THEIR MANUFACTURE | ESSILOR INTERNATIONAL (COMPAGNIE GENERALE D'OPTIQUE) (FR) | 2004-06-02 | — | — | EP | disclosed |
| US-20040084660-A1 | Photochromic bis-naphthopyran compounds and methods for their manufacture | ESSILOR INTERNATIONAL (COMPAGNIE GENERALE D'OPTIQUE) (FR) | 2004-05-06 | — | — | US | disclosed |
| US-20030078441-A1 | Photochromic bis-naphthopyran compounds and methods for their manufacture | ESSILOR INTERNATIONAL (COMPAGNIE GENERALE D'OPTIQUE) (FR) | 2003-04-24 | — | — | US | disclosed |
| WO-2003020718-A1 | PHOTOCHROMIC BIS-NAPHTHOPYRAN COMPOUNDS AND METHODS FOR THEIR MANUFACTURE | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2003-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078441-A1 | Photochromic bis-naphthopyran compounds and methods for their manufacture | CRY1, NQO1, G6PD | HPGD 575/4885KDM4E 2154/4885MEN1 3447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.